  Acute leukemias<disease> in children with CR3 , refractory relapse , or induction failure ( IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia<disease> and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine ( doses 40- 52 mg/m